BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Show more

16 Hartum St, Jerusalem, 9777516, Israel

Medical Devices
Healthcare

Market Cap

595.8M

52 Wk Range

$5.00 - $17.35

Previous Close

$14.88

Open

$14.70

Volume

223,593

Day Range

$14.50 - $15.04

Enterprise Value

631M

Cash

69.13M

Avg Qtr Burn

-759K

Insider Ownership

6.04%

Institutional Own.

29.96%

Qtr Updated

12/31/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date